Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

20 The Scientific Committee Members of the Scientific Committee in 2010 (from left): Felix Niggli, Gerhard Christofori, Primo Schär, Brian A. Hemmings, Maria Blettner, Holger Moch, Martin F. Fey (president), Rolf Marti (head of the Scientific Office), Ellen Benhamou, Freddy Radtke, Martin Pruschy, Adrian Ochsenbein, Cristiana Sessa, Hans-Uwe Simon (not pictured: Kurt Fritzsche and Friedrich Stiefel). The Scientific Committee is responsible for evalua- ting the research grant applications submitted to the Foundation Cancer Research Switzerland and the Swiss Cancer League by researchers seeking research funding. The committee’s peer review process uses strictly defined evaluation criteria (see box, “Criteria for high-quality cancer research”, page 23). The central criterion is always whether a research project is expected to advance our understanding of cancer prevention, causes, or treatment. The 15 members of the Scientific Committee are recognized experts with outstanding achievements and expertise in all areas relevant to cancer research. Having all of the research areas represented on one committee prevents the formation of specialized subcommittees and also assures funding of research trends in all areas. The members serve on the committee for three years and can be re-elected twice.
The president of the Scientific Committee is Prof. Martin F. Fey, MD. The committee members are representatives of the following research areas: – basic biomedical research: 4 members – patient-centred clinical cancer research: 2 members – laboratory-based clinical cancer research: 2 members – epidemiology and cancer prevention: 2 members – psychosocial and other cancer research (public health research): 2 members – translational cancer research: 2 members Each member of the committee handles on average 20 grant applications per year. More than half of the proposals are in basic research. As the time it takes for members to review basic research proposals has reached an upper limit, it has been decided that an additional representative of the discipline can be voted into the Scientific Committee. The Scientific Committee meets twice a year to dis- cuss in detail the research grant applications that have been reviewed by committee members and by external reviewers (see box, “The research grant application review process”). Based on the discussions the committee produces a ranked list of the research proposals that the committee recommends to the boards of the Foundation Cancer Research Switzerland and the Swiss Cancer League for grant approval. As the financial means are limited, it is never possi- ble to approve grants for all proposals that the committee judges to be of good quality and worthy of funding. In the reporting period 2009–2010 there were on average 22 research proposals each year that could not be approved for funding despite their excellent quality. In total the Scientific Committee reviews almost 150 grant applications per year. Operational support for the Scientific Committee’s important tasks and responsibility is provided by the Scientific Office of the Swiss Cancer League and the Foundation Cancer Research Switzerland. It organizes the call for and review of proposals and is responsible for quality control of the supported research projects. The research grant application review process The research proposal is submitted to and recorded by the Scientific Office of the Swiss Cancer League. < The grant application is sent for review to two members of the Scientific Committee who are experts in the relevant specialist field (such as basic research or psycho-oncology). < The two Scientific Committee members recommend additional experts as external reviewers. < The Scientific Office asks the external reviewers to review the proposal. < The reviewers evaluate the proposal. Four to six reviews are obtained for each research proposal, two of which are by Scientific Committee members. < The Scientific Office collects the reviews and puts them in a file. < The research proposal is discussed in detail at the bi-annual meeting of the Scientific Committee. < After the meeting, the Scientific Office writes up detailed minutes and creates a list of all proposals ranked according to the committee’s recommendations. < The ranking list is forwarded to the boards of the Foundation Cancer Research Switzerland and the Swiss Cancer League, which then decide which proposals will be funded. < The Scientific Office notifies the applicant of the decision. Upon request, the reviews are made available to the applicant in an anonymous form. 21
Page 1 and 2: Cancer Research in Switzerland A pu
Page 3 and 4: Cancer Research in Switzerland
Page 5 and 6: Basic biomedical research 55 Cancer
Page 7 and 8: policy work and was in charge of de
Page 9 and 10: The main focus of the research fund
Page 11 and 12: gramme research funding decreased b
Page 13 and 14: Table 2 Distribution of funds for i
Page 15 and 16: Funding patient-centred research Pa
Page 17 and 18: value was not clearly discernible.
Page 19 and 20: New organization of the Foundation
Page 21: The board of the Foundation Cancer
Page 25 and 26: Prof. Martin Pruschy, PhD Departmen
Page 27 and 28: Swartz wants to find out how tumour
Page 29 and 30: The scientific and medical research
Page 31 and 32: 3. The original order/sequence of t
Page 33 and 34: As a federation, the Cancer League
Page 35 and 36: List of funded research projects, i
Page 37 and 38: Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40: Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42: Thurgau Cancer League Biotechnologi
Page 43 and 44: Weller Michael | 2010: CHF 65,828.-
Page 45 and 46: manageable funding of individual pr
Page 47 and 48: enhances breast cancer cell motilit
Page 49 and 50: Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52: International Clinical Cancer Resea
Page 53 and 54: in PHIV were shown for Hodgkin’s
Page 55: Zucca Emanuele et al. | Internation
Page 58 and 59: 56 “hierarchical structure” of
Page 60 and 61: 58 the attempt should be made to st
Page 62 and 63: 60 Gönczy Pierre | KLS 0202402
Page 64 and 65: 62 Romero Pedro | OCS 020110220
Page 66 and 67: 64 Beermann Friedrich | In vivo scr
Page 68 and 69: 66 Christofori Gerhard | Podoplanin
Page 70 and 71: 68 Frei Christian | The function of
Page 72 and 73:
70 cell, this novel mechanism serve
Page 74 and 75:
72 Results The induction of viral p
Page 76 and 77:
74 Hübscher Ulrich | Repair of oxi
Page 78 and 79:
76 Methods and experimental approac
Page 80 and 81:
78 of cMyc and/or NMyc and demo
Page 82 and 83:
80 In summary, this work improves o
Page 84 and 85:
82 Pruschy Martin | Microtubule int
Page 86 and 87:
84 Renner Christoph | Selective inh
Page 88 and 89:
86 Goal Here we build on these obse
Page 90 and 91:
88 by TDG prevents efficient downst
Page 92 and 93:
90 To address these questions, we a
Page 94 and 95:
92 Translational relevance The resu
Page 96 and 97:
94 Grünberg Jürgen | KFS 025460
Page 98 and 99:
96 Tschan Mario P. | KFS 0248608
Page 100 and 101:
98 Boyman Onur | Preclinical testin
Page 102 and 103:
100 Constam Daniel | Role of activi
Page 104 and 105:
102 this study we will examine the
Page 106 and 107:
104 Janscak Pavel | Study of the ro
Page 108 and 109:
106 Müller Anne | The molecular pa
Page 110 and 111:
108 Radtke Freddy | The role of Not
Page 112 and 113:
110 Schär Primo | DNA repair, epig
Page 114 and 115:
112 In this project we will investi
Page 116 and 117:
114
Page 118 and 119:
116 and Research). Other financial
Page 120 and 121:
118 be totally unaffordable for aca
Page 122 and 123:
120 Clinical research List of compl
Page 124 and 125:
122 Hunger Robert E. | OCS 02262-08
Page 126 and 127:
124 Clinical research Presentation
Page 128 and 129:
126 Benhattar Jean | Identification
Page 130 and 131:
128 Bertoni Francesco | Genome-wide
Page 132 and 133:
130 Interpretation ESA treatment in
Page 134 and 135:
132 Our results could pave the way
Page 136 and 137:
134 new drugs that specifically tar
Page 138 and 139:
136 slides in two different concent
Page 140 and 141:
138 Conclusions A strong network of
Page 142 and 143:
140 tions introduced to ARE motifs
Page 144 and 145:
142 Müller Beatrice U. | The maste
Page 146 and 147:
144 A novel method was developed fo
Page 148 and 149:
146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151:
148 Timmermann Beate | Prospective
Page 152 and 153:
150 recurrence of the disease, we a
Page 154 and 155:
152 Zucca Emanuele | A prospective
Page 156 and 157:
154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159:
156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161:
158 activity at the single cell lev
Page 162 and 163:
160 Our research projects aim at un
Page 164 and 165:
162 Körner Meike | In vitro evalua
Page 166 and 167:
164 Nadal David | Is endemic Burkit
Page 168 and 169:
166 (> 50.000/patient). For their a
Page 170 and 171:
168 Zeller Rolf | Functional analys
Page 172 and 173:
170
Page 174 and 175:
172 area of health services researc
Page 176 and 177:
174 The financing of palliative car
Page 178 and 179:
176 National Strategy for Palliativ
Page 180 and 181:
178 Psychosocial research List of c
Page 182 and 183:
180 Within the patient group, level
Page 184 and 185:
182 Further, the results suggest th
Page 186 and 187:
184 It is in this context that the
Page 188 and 189:
186 Recommendation Female spouses o
Page 190 and 191:
188 Psychosocial research Presentat
Page 192 and 193:
190 rates communication skills rema
Page 195 and 196:
Epidemiological research Epidemiolo
Page 197 and 198:
data from cancer registries. In the
Page 199 and 200:
The importance of cancer registries
Page 201 and 202:
Ess Silvia | Patterns of care and s
Page 203 and 204:
Epidemiological research List of ap
Page 205 and 206:
Impact This work will serve as the
Page 207 and 208:
Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?